ICCnotes(beta)

Inherited Cardiac Conditions reference

Open this condition in the interactive app →

Loeys-Dietz Syndrome

Quick Summary

Definition: An autosomal dominant connective tissue disorder of the TGF-β pathway, characterised by arterial tortuosity and aggressive, widespread arterial aneurysm and dissection.[1]

  • Prevalence: Rare (likely under-recognized) - MORE AGGRESSIVE than Marfan[3]
  • Key genes: TGFBR1, TGFBR2 (TGF-β pathway), SMAD3, autosomal dominant
  • Hallmark: Aortic aneurysm + hypertelorism + bifid uvula/cleft palate + arterial tortuosity (NO ectopia lentis)
  • High-risk markers: Dissection at smaller sizes (<42mm), younger age, rapid growth, family history dissection
  • First-line Mx: Beta-blockers, surgical threshold gene-/patient-specific (roughly high-30s to mid-40s mm, lower than Marfan's ~50mm), frequent imaging (6-12 monthly)

Aetiology

Monogenic (Mendelian): TGF-β pathway genes (TGFBR1/2, SMAD3, TGFB2/3)[1]

Genetics

Inheritance: Autosomal dominant; first-degree relatives have a 50% risk of inheriting the pathogenic variant.[1]

Familial vs de novo: Approximately 75% of cases are familial (inherited from an affected parent); approximately 25% arise as de novo mutations, no family history of LDS.[3]

Genes: TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3 (all TGF-β signalling pathway)

Penetrance: High but variable expressivity, even within the same family, severity of aortic involvement may differ significantly.

Prevalence

Estimated prevalence ~1 in 50,000–200,000; likely under-recognized due to phenotypic overlap with Marfan syndrome and other connective tissue disorders.[1]

Exact prevalence unknown; genetic confirmation has expanded the recognised spectrum since 2005.[3]

More aggressive than Marfan syndrome, aortic dissection occurs at smaller diameters and younger ages.

Diagnosis

Diagnosis is molecular: confirmed by a pathogenic variant in TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3 or SMAD2 (types 1–6) in a patient with arterial aneurysm/tortuosity or characteristic features. Gene-panel testing is needed to guide family screening, and the specific gene informs the surgical threshold (most aggressive with TGFBR1/TGFBR2).[3] Baseline head-to-pelvis arterial imaging (CT/MRA) is required at diagnosis.[4]

Classic features (types 1-2):

  • Hypertelorism (widely spaced eyes)
  • Bifid uvula or cleft palate
  • Arterial tortuosity
  • Aortic root aneurysm

MORE AGGRESSIVE than Marfan: Dissection at smaller diameters, younger ages

Distinguish from Marfan: NO ectopia lentis, more craniofacial features, widespread arterial involvement

Investigations

CT/MR angiography: Head-to-pelvis, demonstrates widespread arterial tortuosity; required at baseline, then typically every 2–3 years with the interval individualised by findings and growth[2]

Echo: Aortic root dimensions and mitral valve prolapse assessment[2]

Genetic testing: Multi-gene panel covering TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3[1]

Treatments

1. General measures:

  • Avoid vigorous isometric exercise, contact sports; similar lifestyle restrictions as Marfan but stricter
  • Pan-arterial surveillance, cervical, mesenteric, renal, iliac vessels also at risk: echo/CT/MRI every 6–12 months (more frequent than Marfan); full-body MRA at baseline and every 2–3 years (entire arterial tree)
  • Genetic counselling and family cascade testing, see the Genetic Testing page

2. Medical therapy:

  • Aims to reduce haemodynamic stress (same agents as Marfan; more aggressive targets[2])
  • Beta-blockers (first-line):
    • Atenolol: start 25–50 mg once daily → target 50–100 mg once daily; target resting HR <60–65 bpm
    • Bisoprolol: start 2.5 mg once daily → 5–10 mg once daily
    • More aggressive HR targets than Marfan given higher dissection risk at smaller diameters
  • ARB, losartan (Class IIa): Start 25–50 mg once daily → 100 mg once daily; target systolic BP <120–130 mmHg; beneficial for TGF-β pathway suppression

3. Surgery, generally a lower threshold than Marfan but gene- and patient-specific, not a single universal number:

  • Thresholds discussed in the literature range roughly from the high-30s to mid-40s mm depending on gene (TGFBR1/TGFBR2 generally lower/more aggressive than SMAD2, SMAD3, TGFB2, TGFB3), growth rate, family history of dissection, body size, extra-aortic features, and patient preference; the decision should be individualized by an aortopathy MDT rather than applied as a fixed cut-off[2][4]

4. Advanced heart failure and/or transplant referral:

  • Standard advanced-heart-failure pathways apply if severe valve disease leads to LV dysfunction and refractory heart failure
Related Resources

Complications

  • Arterial aneurysm and dissection throughout the arterial tree: at smaller diameters and younger ages than Marfan[1]
  • Arterial tortuosity: with risk of organ and uterine rupture
  • High peripartum vascular risk.

Risk Stratification

Very high dissection risk even at smaller diameters

Pregnancy Management

Pregnancy in Loeys-Dietz syndrome - very high risk, individualized by gene and phenotype

Pregnancy in Loeys-Dietz syndrome carries a genuinely elevated risk of arterial dissection, but the magnitude of that risk is gene-, variant-, patient- and phenotype-specific, not a single fixed figure. Older case series quoting maternal mortality of 25-50% predate current classification and management and should not be presented as a general estimate for all LDS pregnancies.[1][3][5]

Pre-pregnancy assessment:

  • Full arterial tree imaging (head-to-pelvis CT/MR angiography) to establish baseline dimensions, growth trajectory, tortuosity and branch-vessel disease
  • Review of the specific gene involved: TGFBR1/TGFBR2 is generally associated with more aggressive disease than SMAD2, SMAD3, TGFB2 or TGFB3, and this should inform (not by itself determine) risk counselling
  • Prior dissection or aortic surgery, family history of dissection, and current arterial dimensions all contribute to individual risk

Counselling: non-directive pre-pregnancy counselling should describe the range of reported risk, explain that dissection can occur outside the aortic root and at dimensions that would not otherwise prompt surgery, and cover the full range of options including continuing pregnancy with specialist surveillance, deferring pregnancy pending further assessment or intervention, and alternative family-building options (surrogacy, adoption). The decision belongs to the patient.[5]

If pregnancy occurs or continues: care should be led by a Pregnancy Heart Team (cardiology, aortopathy/vascular surgery, maternal-fetal medicine, clinical genetics, obstetric anaesthesia) using an individualized surveillance and delivery plan. Surveillance frequency, imaging modality and interval, activity advice, and threshold for earlier delivery should be set by that team based on the patient's specific gene, baseline dimensions, growth rate and symptoms, not a fixed universal schedule.[5]

Delivery: timing and mode (vaginal vs caesarean, and anaesthetic approach) should be decided by the multidisciplinary team based on aortic status at the time, not a universal preterm caesarean rule.[5]

Postpartum: dissection risk continues into the postpartum period and surveillance should continue for at least several weeks, with the exact schedule again set by the MDT rather than a fixed protocol.

Contraception and future pregnancy: discuss the full range of contraceptive options, including long-acting reversible contraception and permanent methods, through non-directive counselling; the decision, including whether to consider a future pregnancy, is led by the patient.

Follow-up

Based on ESC aortic-disease guidelines and Loeys-Dietz expert consensus[2][3][4].

Advanced / complicated = an aneurysm at or approaching the gene-specific surgical threshold, rapid growth, branch-vessel/arterial aneurysm, or prior dissection/repair.

Genotype-positive / phenotype-negative (G+/P−) = a confirmed pathogenic-variant carrier with no overt disease expression yet.

Genotype+ / Phenotype−Uncomplicated / StableAdvanced / Complicated
FrequencyEvery 6–12 months (from diagnosis)Every 6–12 monthsEvery 3–6 months
Clinical reviewSymptoms, strict BP controlSymptoms, BP control (strict)As above
Echocardiography (aortic root)6–12 monthlyEvery 6–12 months6-monthly or sooner
Head-to-pelvis CT / MR angiographyBaseline head-to-pelvis, then 1–2-yearly (extend if no distal disease)Baseline head-to-pelvis; interval individualised, toward 2-yearly if no distal/branch-vessel diseaseAnnual or sooner
Cervical / cerebral imagingBaselinePeriodic (arterial tortuosity, aneurysm)As indicated
PregnancyHigh-risk; pre-conception counsellingHigh-risk; pre-conception counselling essentialFrequent aortic imaging
Family screening–Cascade imaging + genetics–

Disclaimer: This table is general guidance based on published guidelines and does not replace clinical judgement. The responsible clinician is accountable for determining the appropriate, individualised follow-up plan for each patient.

Key Points

  • Image entire arterial tree - can dissect anywhere (head-to-pelvis CT/MR angiography)[1]
  • Generally more aggressive than Marfan, with a lower surgical threshold, but the exact threshold is gene- and patient-specific, not a fixed number[1]
  • PREGNANCY VERY HIGH RISK (risk varies by gene, prior dissection, arterial dimensions and growth rate; requires pre-pregnancy aortopathy, genetics and cardio-obstetric MDT review)[1]
  • If pregnancy occurs: frequent surveillance; delivery timing and mode set by the MDT; dissection risk persists for at least 12 weeks postpartum
  • Non-directive counselling about the high maternal risk of future pregnancy; offer all highly effective contraceptive options (LARC, sterilisation), patient-led choice

References & Review Date

Last reviewed: July 2026

  1. Loeys BL, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–281. doi:10.1038/ng1511
  2. Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873–2926. doi:10.1093/eurheartj/ehu281
  3. MacCarrick G, et al. Loeys–Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014;16(8):576–587. doi:10.1038/gim.2014.11
  4. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45:3538–3700. doi:10.1093/eurheartj/ehae179
  5. 2025 ESC Guidelines for the management of cardiovascular disease during pregnancy. Eur Heart J. 2025. doi:10.1093/eurheartj/ehaf193